IF-RT alone remains as the Gold Standard for stage IA nodular lymphocyte-predominant Hodgkin Lymphoma

被引：0
作者：
Pilz, Karoline [1 ,2 ]
Jentsch, Christina [1 ,2 ]
Krause, Mechthild [1 ,2 ]
机构：
[1] Tech Univ Dresden, Fak Med, Klin & Poliklin Strahlentherapie & Radioonkol, NCT, Fetscherstr 74, D-01307 Dresden, Germany
[2] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Fetscherstr 74, D-01307 Dresden, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2016年 / 192卷 / 06期
关键词：
EUROPEAN TASK-FORCE; PHASE-2; TRIAL; DISEASE; RADIOTHERAPY; RITUXIMAB; THERAPY; PROJECT; CANCER;
D O I：
10.1007/s00066-016-0975-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：428 / 430
页数：3
相关论文
共 18 条
  • [1] Anagnostopoulos I, 2000, BLOOD, V96, P1889
  • [2] LONG-TERM TOXICITY OF EARLY STAGES OF HODGKINS-DISEASE THERAPY - THE EORTC EXPERIENCE
    COSSET, JM
    HENRYAMAR, M
    MEERWALDT, JH
    [J]. ANNALS OF ONCOLOGY, 1991, 2 : 77 - 82
  • [3] Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's disease
    Diehl, V
    Sextro, M
    Franklin, J
    Hansmann, ML
    Harris, N
    Jaffe, E
    Poppema, S
    Harris, M
    Franssila, K
    van Krieken, J
    Marafioti, T
    Anagnostopoulos, I
    Stein, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 776 - 783
  • [4] Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group
    Eichenauer, Dennis A.
    Pluetschow, Annette
    Fuchs, Michael
    von Tresckow, Bastian
    Boell, Boris
    Behringer, Karolin
    Diehl, Volker
    Eich, Hans Theodor
    Borchmann, Peter
    Engert, Andreas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (26) : 2857 - +
  • [5] Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial
    Ekstrand, BC
    Lucas, JB
    Horwitz, SM
    Fan, Z
    Breslin, S
    Hoppe, RT
    Natkunam, Y
    Bartlett, NL
    Horning, SJ
    [J]. BLOOD, 2003, 101 (11) : 4285 - 4289
  • [6] Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma
    Hodgson, David C.
    Koh, Eng-Siew
    Tran, Tu Huan
    Heydarian, Mostafa
    Tsang, Richard
    Pintilie, Melania
    Xu, Tony
    Huang, Lei
    Sachs, Rainer K.
    Brenner, David J.
    [J]. CANCER, 2007, 110 (11) : 2576 - 2586
  • [7] Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines
    Hoppe, Richard T.
    Advani, Ranjana H.
    Ai, Weiyun Z.
    Ambinder, Richard F.
    Aoun, Patricia
    Bello, Celeste M.
    Bierman, Philip J.
    Blum, Kristie A.
    Chen, Robert
    Dabaja, Bouthaina
    Duron, Ysabel
    Forero, Andres
    Gordon, Leo I.
    Hernandez-Ilizaliturri, Francisco J.
    Hochberg, Ephraim P.
    Maloney, David G.
    Mansur, David
    Mauch, Peter M.
    Metzger, Monika
    Moore, Joseph O.
    Morgan, David
    Moskowitz, Craig H.
    Poppe, Matthew
    Pro, Barbara
    Winter, Jane N.
    Yahalom, Joachim
    Sundar, Hema
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (05): : 589 - 597
  • [8] A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk
    Koh, Eng-Siew
    Tran, Tu Huan
    Heydarian, Mostafa
    Sachs, Rainer K.
    Tsang, Richard W.
    Brenner, David J.
    Pintilie, Melania
    Xu, Tony
    Chung, June
    Paul, Narinder
    Hodgson, David C.
    [J]. RADIATION ONCOLOGY, 2007, 2 (1)
  • [9] NICHOLAS DS, 1990, HISTOPATHOLOGY, V16, P157
  • [10] Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage 1A lymphocyte-predominant Hodgkin's lymphoma:: a retrospective analysis from the German Hodgkin Study Group (GHSG)
    Nogová, L
    Reineke, T
    Eich, HT
    Josting, A
    Müller-Hermelink, HK
    Wingbermühle, K
    Brillant, C
    Gossmann, A
    Oertel, J
    Bollen, MV
    Müller, RP
    Diehl, V
    Engert, A
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (10) : 1683 - 1687
12